# Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

> **NCT03168139** · PHASE1,PHASE2 · COMPLETED · sponsor: **TME Pharma AG** · enrollment: 20 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Olaptesed pegol - Monotherapy
- **DRUG:** Olaptesed pegol + Pembrolizumab - Combination Therapy

## Key facts

- **NCT ID:** NCT03168139
- **Lead sponsor:** TME Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2020-03-25
- **Final completion:** 2020-03-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168139, "Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03168139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*